Show simple item record

dc.contributor.authorBlanco Ayala, Tonali
dc.contributor.authorRamírez Ortega, Daniela
dc.contributor.authorOvalle Rodríguez, Paulina
dc.contributor.authorPineda, Benjamín
dc.contributor.authorPérez de la Cruz, Gonzalo
dc.contributor.authorGonzález Esquivel, Dinora
dc.contributor.authorSchwarcz, Robert
dc.contributor.authorSathyasaikumar, Korrapati V.
dc.contributor.authorJiménez Anguiano, Anabel
dc.contributor.authorPérez de la Cruz, Verónica
dc.date.accessioned2021-02-12T17:57:25Z
dc.date.available2021-02-12T17:57:25Z
dc.date.issued2021-01-20
dc.identifier.urihttp://hdl.handle.net/10713/14689
dc.description.abstractThe tryptophan (Trp) metabolite kynurenic acid (KYNA) is an α7-nicotinic and N-methyl-d-aspartate receptor antagonist. Elevated brain KYNA levels are commonly seen in psychiatric disorders and neurodegenerative diseases and may be related to cognitive impairments. Recently, we showed that N-acetylcysteine (NAC) inhibits kynurenine aminotransferase II (KAT II), KYNA's key biosynthetic enzyme, and reduces KYNA neosynthesis in rats in vivo. In this study, we examined if repeated systemic administration of NAC influences brain KYNA and cognitive performance in mice. Animals received NAC (100 mg/kg, i.p.) daily for 7 days. Redox markers, KYNA levels, and KAT II activity were determined in the brain. We also assessed the effect of repeated NAC treatment on Trp catabolism using brain tissue slices ex vivo. Finally, learning and memory was evaluated with and without an acute challenge with KYNA's bioprecursor L-kynurenine (Kyn; 100 mg/kg). Subchronic NAC administration protected against an acute pro-oxidant challenge, decreased KYNA levels, and lowered KAT II activity and improved memory both under basal conditions and after acute Kyn treatment. In tissue slices from these mice, KYNA neosynthesis from Trp or Kyn was reduced. Together, our data indicate that prolonged treatment with NAC may enhance memory at least in part by reducing brain KYNA levels.en_US
dc.description.urihttps://doi.org/10.3390/antiox10020147en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofAntioxidants (Basel, Switzerland)en_US
dc.subjectN-acetylcysteineen_US
dc.subjectkynurenic aciden_US
dc.subjectkynurenineen_US
dc.subjectlearning and memoryen_US
dc.titleSubchronic N-acetylcysteine Treatment Decreases Brain Kynurenic Acid Levels and Improves Cognitive Performance in Mice.en_US
dc.typeArticleen_US
dc.identifier.doi10.3390/antiox10020147
dc.identifier.pmid33498402
dc.source.volume10
dc.source.issue2
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record